Fresh analysis reveals that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end traditional diet and exercise plans.
Findings released in a major health publication shows that while obese individuals can lose a large proportion of their total mass while on the medication, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People using these drugs need to be cognizant of the danger of rapid weight regain when the treatment concludes," warns researcher Dr. Susan Jebb.
This pace of recovery suggests a return to starting mass within about 18 months.
Weighing Treatments
The analysis, which reviewed 37 of trials involving thousands of patients, contrasted the results of GLP-1 agonists with other pills.
Researchers point out that individuals who shed pounds through lifestyle changes alone generally have a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Fast Rebound
Nutrition scientists propose the way of the injections explains the heightened rebound.
The injections copy a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of GLP-1 levels several times higher than normal could lead to the body to produce less of its own natural hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement leads to hunger is uncontrolled, making overeating a significant risk."
A Lifelong Disease?
The NHS advise the jabs for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, due to the likelihood of weight regain, the treatment should be considered long-term.
This opinion is supported by pharmaceutical companies, who note that the results "underscore the chronic nature of excess weight," similar to managing diseases like diabetes.
Patient Experiences
Individuals who have discontinued the medication explain a intense return of appetite.
"It felt as if a trigger flipping and you're instantly starving," recalled an individual.
This difficulty is worsened if patients have not established permanent dietary or behavioural modifications during treatment.
Significant Adoption
Survey data indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Use is higher among women compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, experts stress that while GLP-1 drugs are potent tools for weight loss, they are not a magic cure and maintained weight loss hinges on combined lifestyle support.
